XML 1055 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
COMMITMENTS AND CONTINGENCIES (Details Narrative)
1 Months Ended 3 Months Ended 4 Months Ended 9 Months Ended 12 Months Ended
Aug. 08, 2017
Oct. 02, 2016
USD ($)
shares
May 31, 2017
EUR (€)
Oct. 25, 2016
USD ($)
Jun. 30, 2016
USD ($)
May 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Jan. 31, 2015
USD ($)
Sep. 30, 2014
USD ($)
Aug. 31, 2012
USD ($)
Sep. 30, 2017
USD ($)
shares
Sep. 30, 2016
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
shares
Sep. 30, 2016
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Jun. 21, 2016
USD ($)
Operating lease periodic payment               $ 730         $ 709          
Frequency of periodic payment               Monthly         Monthly          
Operating lease rental expense                     $ 2,126 $ 2,126   $ 6,377 $ 2,834 $ 4,960 $ 12,053  
Operating lease expiration date               Nov. 30, 2015                    
Decahedron [member]                                    
Operating lease periodic payment       $ 2,415                            
Operating lease rental expense                           19,580        
Term of operating lease       1 year                            
Private Placement [Member]                                    
Commitments and contingencies description

(1) a cash commission of 6% of the total gross proceeds for two named investors (2) a cash commission of 4% of total gross proceeds from five named investors and (3) excluding the five named investors in “(2)” a cash commission equal to 8% of the total gross proceeds from the Offering and the issuance to the Agent or its designees of warrants covering 8% of the shares of common stock issued or issuable by the Company in the Offering. Additionally, the Agent will receive a cash fee of 8% payable within 5 business days, but only in the event of, the receipt by the Company of any cash proceeds from the exercise of any warrants with an expiration equal to or less than 24 months sold in the Offering

                                 
Amplerissimo [Member]                                    
Operating lease periodic payment                   $ 122                
Frequency of periodic payment                   Monthly                
Operating lease rental expense                     368 368   1,105 1,103 1,462 1,462  
Operating lease expiration date                   Jul. 31, 2013                
Operating lease renewal date                   Jul. 31, 2015                
SkyPharm [Member]                                    
Operating lease periodic payment     € 1,250           $ 4,802                  
Operating lease rental expense                     $ 30,094 $ 25,961   84,710 64,127 $ 89,323 $ 60,614  
Term of operating lease                 6 years                  
SkyPharm [Member] | Additional space [Member]                                    
Operating lease periodic payment         $ 2,021 $ 886                        
SkyPharm [Member] | First Floor [Member]                                    
Operating lease periodic payment             $ 886                      
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member]                                    
Operating lease periodic payment   $ 1,500                                
Common stock shares reserved | shares   200,000                                
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | Conclusion of Phase III testing [Member]                                    
Common stock shares reserved | shares   50,000                                
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | Conclusion of Phase II testing [Member]                                    
Common stock shares reserved | shares   50,000                                
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | conclusion of Phase I testing [Member]                                    
Common stock shares reserved | shares   50,000                                
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | Conclusion of Preclinical Trials [Member]                                    
Common stock shares reserved | shares   50,000                                
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member]                                    
Operating lease periodic payment                           $ 1,500        
Common stock shares reserved | shares                     200,000     200,000        
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] | Conclusion of Phase III testing [Member]                                    
Common stock shares reserved | shares                     50,000     50,000        
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] | Conclusion of Phase II testing [Member]                                    
Common stock shares reserved | shares                     50,000     50,000        
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] | conclusion of Phase I testing [Member]                                    
Common stock shares reserved | shares                     50,000     50,000        
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] | Conclusion of Preclinical Trials [Member]                                    
Common stock shares reserved | shares                     50,000     50,000        
CC Pharma GmbH [Member]                                    
Non-refundable fee                                   $ 454,800
Expense paid                             $ 454,800